

Primary Care Rebate Schemes (PCRS)

As of July 2019, Barking and Dagenham, Havering and Redbridge Clinical Commissioning Groups currently has signed up to the following primary care rebates (Company name – product(s) - (agreement start/expiry dates)):

Medicines

- Aymes - Aymes Complete/Crème/2kcal/Shake starter (1st January 2019 – 31st December 2019) thereafter rebate shall continue until agreement terminated by either party)
- AstraZeneca - Zoladex (Gosarelin) (1st October 2015 – 31st December 2019) thereafter rebate shall continue until agreement terminated by either party)
- Chiesi Ltd – Clenil (betamethasone dipropionate) (1st July 2019 – 30th June 2021)
- Daiichi Sankyo UK Ltd - Edoxaban (1st November 2018 – 31st December 2022)
- Ferring Pharmaceuticals Ltd – Firmagon (Degarelix) (1st January 2017 – 31st August 2020)
- Fontus Health Ltd - Luventa XL (Galantamine) (1st April 2016 – until agreement terminated by either party)
- Fontus Health Ltd - Zaluron XL (Quetiapine) (1st April 2016 – until agreement terminated by either party)
- GSK - Seretide (Fluticasone/Salmeterol) (1st January 2018 – 31st March 2020)
- Intrapharm Laboratories Ltd - Aquamax (1st December 2018 – 30th November 2020)
- Intrapharm Laboratories Ltd - Carbocisteine (1st December 2018 – 30th November 2020)
- Kyowa Kirin Ltd - Adcal D3 (Calcium Carbonate/Colecalciferol) (1st October 2015 – until agreement terminated by either party)
- Kyowa Kirin Ltd - Stexerol D3 (Colecalciferol) (1st April 2019 - until agreement terminated by either party)
- Merck Serono - Glucophage SR (Metformin SR) (1st January 2013 – 31st March 2021)
- MSD - Januvia (sitagliptin) – (1st September 2017- 31st July 2020)
- Sandoz - AirFluSal ForSpiro (Fluticasone/Salmeterol) (1st August 2018 – 31st July 2020)
- Sandoz - AirFluSal MDI (Fluticasone/Salmeterol) (1st August 2018 – 30th September 2019)
- Takeda - Prostag (Leuprorelin) (1st April 2018 – 31st March 2020 thereafter rebate shall continue for 12 monthly rollover until agreement terminated by either party)

Appliances

- Bayer - Contour Next (1st April 2014 – 31st October 2019)

Food supplements

- Fontus Health Ltd - Fontus Health Range of Food Supplements (1st July 2014 –30th June 2021)

Accountable Officer: Jane Milligan
Managing Director: Ceri Jacob
Barking and Dagenham, Havering and Redbridge Clinical Commissioning Groups

Chairs:
Dr Jagan John, Barking and Dagenham Clinical Commissioning Group
Dr Atul Aggarwal, Havering Clinical Commissioning Group
Dr Anil Mehta, Redbridge Clinical Commissioning Group

Primary Care Rebate Schemes (PCRS)

Terminated agreements

- Agamatrix - WaveSense Jazz (1st January 2014 – 31st January 2018)
- AstraZeneca - Oxis (1st January 2016 – 31st December 2018)
- AstraZeneca - Symbicort (1st January 2016 – 31st December 2017)
- Neon Diagnostics - GlucoLab (1st January 2014 – 31st December 2016)
- Sanofi - Apidra, Insuman and Lantus (Insulin portfolio) (1st April 2014 – 31st March 2017)
- Sanofi - Clexane (1st July 2015 – 31st March 2018)
- GlucoRx - Lancets (1st January 2014 – 30th April 2019)
- GlucoRx - Nexus (1st January 2014 – 30th April 2019)
- GlucoRx - Pen Needles (1st August 2014 – 30th April 2019)

Accountable Officer: Jane Milligan
Managing Director: Ceri Jacob
Barking and Dagenham, Havering and Redbridge Clinical Commissioning Groups

Chairs:
Dr Jagan John, Barking and Dagenham Clinical Commissioning Group
Dr Atul Aggarwal, Havering Clinical Commissioning Group
Dr Anil Mehta, Redbridge Clinical Commissioning Group